跳至主要内容
临床试验/NCT05557123
NCT05557123已完成不适用

The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients With Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)

Seoul National University Bundang Hospital2 个研究点 分布在 2 个国家目标入组 637 人开始时间: 2022年3月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
637
试验地点
2
主要终点
Drug adherence

研究概览

简要总结

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
  • patients who already took or plan to take rivoxban
  • patients who able to use smart phone

排除标准

  • creatinine clearance <15ml/min
  • moderate or severe mitral stenosis
  • mitral valve operation history
  • current alcohol abuse or alcohol abus history
  • Not eligible for study due to legal or psychiatric problem
  • enrolled other clinical study within 4 weeks
  • declined to enroll the study

研究组 & 干预措施

MEDI-app

Experimental

conventional treatment with MEDI-app feedback

干预措施: MEDI-app (Device)

conventional treatment

No Intervention

conventional treatment

结局指标

主要结局

Drug adherence

时间窗: 24 week

Drug adherence by pill count

Proportion of adequate medication adherence at 24 weeks

时间窗: 24 weeks

proportion of patients with ≥95% of continuous medication adherence

次要结局

  • The occurrence of Thromboembolism (Stroke, TIA, Pulmonary embolism)(24 week)
  • The occurrence of bleeding(24 week)
  • Drug adherence(12 week)
  • The occurrence of clinical composite end point(24 week)
  • The occurrence of MACCE and hospitalization(24 week)
  • Proportion of adequate medication adherence at 12 weeks(12 week)
  • medication adherence by zero-inflated model(12 week and 24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dong-Ju Choi

Professor

Seoul National University Bundang Hospital

研究点 (2)

Loading locations...

相似试验